镥-177-PSMA-617治疗转移性去势抵抗性前列腺癌:VISION试验的局限性
本文评述VISION试验的局限性:对照组标准治疗选择受限、部分初始被认为不适合紫杉烷的患者后来接受了紫杉烷治疗、脱落率高;并指出镥-177-PSMA-617的直接和间接成本可能使许多国家无法获得该疗法,加深全球医疗可及性不平等。
要点
- VISION试验对照组存在三方面局限:标准治疗选择受限、部分初始不适合紫杉烷者后续接受紫杉烷、脱落率高。
- VISION是现代肿瘤试验众多挑战的一个例子。
- 镥-177-PSMA-617的直接和间接成本可能使许多国家无法获得该疗法,加深全球医疗可及性不平等。
核心结论
- VISION试验存在三方面影响对照组的局限性:标准治疗选择受限、部分初始被认为不适合紫杉烷的患者后来接受了紫杉烷治疗、脱落率高。
主要发现
- VISION试验中影响对照组的局限性包括:标准治疗选择受限、部分初始被认为不适合紫杉烷的患者后来接受了紫杉烷治疗、脱落率高。
临床怎么用
- 镥-177-PSMA-617的直接和间接成本可能使许多国家无法获得该疗法,加深全球医疗可及性不平等。
局限性
- VISION试验影响对照组的局限性包括:标准治疗选择受限、部分初始被认为不适合紫杉烷的患者后来接受了紫杉烷治疗、脱落率高。
- 镥-177-PSMA-617的直接和间接成本可能使许多国家无法获得该疗法,加深全球医疗可及性不平等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lu-PSMA was approved in the USA for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer already treated with androgen receptor pathway inhibition and taxane-based chemotherapy on the basis of results from VISION. Three limitations affected the control arm in VISION: choice of the standard of care was limited, some patients initially deemed ineligible for taxane later received it, and there was a high attrition rate. VISION is an example of the many challenges in modern oncology trials. The direct and indirect costs of Lu-PSMA also mean that this therapy is likely to be out of reach for many nations, deepening global inequities in health care access.
引用
- Olivier T, Powell K, Prasad V, et al. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2022. PMID: 36096857. doi:10.1016/j.eururo.2022.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。